However, ADAMTS-13 levels were lower at baseline in patients with unfavorable clinical outcomes at 90 days after thrombolysis than in patients with favorable clinical outcomes, but when the results were adjusted for age, history of atrial fibrillation, glycemia, baseline National Institute of Health stroke scale score, and Trial of Org 10172 in Acute Stroke Treatment classification, no difference in ADAMTS-13 levels was found [29]. The gene discussed is ADAMTS13; the disease is stroke disorder.